{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:09Z","timestamp":1791353769912,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/leu.2017.57","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T08:19:52Z","timestamp":1487233192000},"page":"2191-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":196,"title":["Fully human CD19-specific chimeric antigen receptors for T-cell therapy"],"prefix":"10.1038","volume":"31","author":[{"given":"D","family":"Sommermeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Shamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A I","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K M","family":"Mohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"BFleu201757_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imr.12139","volume":"257","author":"MC Jensen","year":"2014","unstructured":"Jensen MC, Riddell SR . Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014; 257: 127\u2013144.","journal-title":"Immunol Rev"},{"key":"BFleu201757_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA . Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267\u2013276.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201757_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126: 2123\u20132138.","journal-title":"J Clin Invest"},{"key":"BFleu201757_CR4","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra225.","journal-title":"Sci Transl Med"},{"key":"BFleu201757_CR5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509\u20131518.","journal-title":"N Engl J Med"},{"key":"BFleu201757_CR6","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.","journal-title":"Sci Transl Med"},{"key":"BFleu201757_CR7","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709\u20132720.","journal-title":"Blood"},{"key":"BFleu201757_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725\u2013733.","journal-title":"N Engl J Med"},{"key":"BFleu201757_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507\u20131517.","journal-title":"N Engl J Med"},{"key":"BFleu201757_CR10","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822\u20131826.","journal-title":"J Clin Invest"},{"key":"BFleu201757_CR11","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817\u20134828.","journal-title":"Blood"},{"key":"BFleu201757_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nm0296-216","volume":"2","author":"SR Riddell","year":"1996","unstructured":"Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216\u2013223.","journal-title":"Nat Med"},{"key":"BFleu201757_CR13","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","volume":"107","author":"C Berger","year":"2006","unstructured":"Berger C, Flowers ME, Warren EH, Riddell SR . Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294\u20132302.","journal-title":"Blood"},{"key":"BFleu201757_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","volume":"117","author":"CH Lamers","year":"2011","unstructured":"Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011; 117: 72\u201382.","journal-title":"Blood"},{"issue":"20 Pt 1","key":"BFleu201757_CR15","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12 (20 Pt 1): 6106\u20136115.","journal-title":"Clin Cancer Res"},{"key":"BFleu201757_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1: 26\u201331.","journal-title":"Cancer Immunol Res"},{"key":"BFleu201757_CR17","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","volume":"183","author":"Y Zhao","year":"2009","unstructured":"Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563\u20135574.","journal-title":"J Immunol"},{"key":"BFleu201757_CR18","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr3674","volume":"16","author":"M Sun","year":"2014","unstructured":"Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y . Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res 2014; 16: R61.","journal-title":"Breast Cancer Res"},{"key":"BFleu201757_CR19","doi-asserted-by":"publisher","first-page":"275ra222","DOI":"10.1126\/scitranslmed.aaa4963","volume":"7","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7: 275ra222.","journal-title":"Sci Transl Med"},{"key":"BFleu201757_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/mt.2011.256","volume":"20","author":"E Lanitis","year":"2012","unstructured":"Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 2012; 20: 633\u2013643.","journal-title":"Mol Ther"},{"key":"BFleu201757_CR21","doi-asserted-by":"crossref","first-page":"21533","DOI":"10.18632\/oncotarget.4071","volume":"6","author":"DG Song","year":"2015","unstructured":"Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr . A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 2015; 6: 21533\u201321546.","journal-title":"Oncotarget"},{"key":"BFleu201757_CR22","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1038\/mtna.2013.19","volume":"2","author":"V Alonso-Camino","year":"2013","unstructured":"Alonso-Camino V, Sanchez-Martin D, Compte M, Nunez-Prado N, Diaz RM, Vile R et al. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors. Mol Ther Nucleic Acids 2013; 2: e93.","journal-title":"Mol Ther Nucleic Acids"},{"key":"BFleu201757_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","volume":"119","author":"S Terakura","year":"2012","unstructured":"Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR . Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119: 72\u201382.","journal-title":"Blood"},{"key":"BFleu201757_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015; 3: 125\u2013135.","journal-title":"Cancer Immunol Res"},{"key":"BFleu201757_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/104303403322167993","volume":"14","author":"B Engels","year":"2003","unstructured":"Engels B, Cam H, Schuler T, Indraccolo S, Gladow M, Baum C et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155\u20131168.","journal-title":"Hum Gene Ther"},{"key":"BFleu201757_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ et al. Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30: 492\u2013500.","journal-title":"Leukemia"},{"key":"BFleu201757_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118: 1255\u20131263.","journal-title":"Blood"},{"key":"BFleu201757_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00109-008-0317-3","volume":"86","author":"M Leisegang","year":"2008","unstructured":"Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue SA et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 2008; 86: 573\u2013583.","journal-title":"J Mol Med"},{"key":"BFleu201757_CR29","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","volume":"19","author":"M Hudecek","year":"2013","unstructured":"Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013; 19: 3153\u20133164.","journal-title":"Clin Cancer Res"},{"issue":"Web Server issu","key":"BFleu201757_CR30","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkn202","volume":"36","author":"C Lundegaard","year":"2008","unstructured":"Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M . NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008; 36 (Web Server issue): W509\u2013W512.","journal-title":"Nucleic Acids Res"},{"key":"BFleu201757_CR31","unstructured":"Wagner RW, Litovchick A, Chen Y Protein screening methods. US Patent No: US9134304 B2 2015.."},{"key":"BFleu201757_CR32","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/emboj.2013.79","volume":"32","author":"C Steentoft","year":"2013","unstructured":"Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 2013; 32: 1478\u20131488.","journal-title":"EMBO J"},{"key":"BFleu201757_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1479-5876-11-23","volume":"11","author":"SN De Oliveira","year":"2013","unstructured":"De Oliveira SN, Wang J, Ryan C, Morrison SL, Kohn DB, Hollis RP . A CD19\/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors. J Transl Med 2013; 11: 23.","journal-title":"J Transl Med"},{"key":"BFleu201757_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21: 581\u2013590.","journal-title":"Nat Med"},{"key":"BFleu201757_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","volume":"3","author":"MJ Frigault","year":"2015","unstructured":"Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015; 3: 356\u2013367.","journal-title":"Cancer Immunol Res"},{"key":"BFleu201757_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS . Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 2016; 6: 133\u2013146.","journal-title":"Cancer Discov"},{"key":"BFleu201757_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","volume":"3","author":"C Berger","year":"2015","unstructured":"Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 2015; 3: 206\u2013216.","journal-title":"Cancer Immunol Res"},{"key":"BFleu201757_CR38","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015; 5: 1282\u20131295.","journal-title":"Cancer Discov"},{"key":"BFleu201757_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517\u2013528.","journal-title":"Lancet"},{"key":"BFleu201757_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 2016; 44: 380\u2013390.","journal-title":"Immunity"},{"key":"BFleu201757_CR41","doi-asserted-by":"publisher","first-page":"28164","DOI":"10.18632\/oncotarget.4461","volume":"6","author":"LE Lamberts","year":"2015","unstructured":"Lamberts LE, de Groot DJ, Bense RD, de Vries EG, Fehrmann RS . Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget 2015; 6: 28164\u201328172.","journal-title":"Oncotarget"},{"key":"BFleu201757_CR42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136\u2013140.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201757_CR43","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014; 6: 261ra151.","journal-title":"Sci Transl Med"},{"issue":"suppl 5","key":"BFleu201757_CR44","doi-asserted-by":"publisher","first-page":"v110","DOI":"10.1093\/neuonc\/nov218.15","volume":"17","author":"D O'Rourke","year":"2015","unstructured":"O'Rourke D, Desai A, Morrissette J, Martinez-Lage M, Nasrallah M, Brem S et al. Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, November 19\u201322, 2015, San Antonio, Texas: IMCT-15 pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Neuro-Oncology 2015; 17 (suppl 5): v110\u2013v111.","journal-title":"Neuro-Oncology"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201757","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.57","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu201757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:31:12Z","timestamp":1648747872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFleu201757"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.57","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]},"assertion":[{"value":"4 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SRR is founder and shareholder of Juno Therapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}